AVTR
Medical Instruments & Supplies · Healthcare
CEO
Equibles does not estimate personal net worth.
Get an email with a short summary when Avantor, Inc. publishes a filing, an earnings call transcript or a press release.
Get AVTR alertsMichael Stubblefield is recorded as CEO at Avantor, Inc. (AVTR). The newest filing on record that lists Michael Stubblefield as CEO at Avantor, Inc. (AVTR) is dated April 13, 2021. The proxy statement of Avantor, Inc. reports total compensation of $13,077,931 for Michael Stubblefield in fiscal 2025, including a base salary of $1,140,000. Disclosed compensation is on record for 7 fiscal years. Michael Stubblefield has spoken on 22 earnings calls across 1 company, most recently for Avantor, Inc. on August 1, 2025. Avantor, Inc. is classified in the Medical Instruments & Supplies industry within the Healthcare sector. Other leadership on record at Avantor, Inc. includes Gregory L. Summe (Chairman), R. Brent Jones (CFO), Thomas Szlosek (CFO) and 7 others.
“Before we discuss our second quarter results, I want to briefly address the leadership transition we announced last week. As many of you saw, Emmanuel Ligner has been appointed Avantour's next CEO effective August 18th.”
“Before we get into our first quarter results, I want to address the CEO transition announcement we made this morning. After careful consideration, our board of directors and I agreed that now is the right time to initiate a transition in Avantour's leadership.”
“We are pleased with the momentum in our business in 2024, including our Q4 performance. There were several notable highlights, including exiting the year with high single-digit organic growth in bioprocessing.”
“We delivered another solid quarter with in-line performance across all key financial metrics. Reported revenue increased sequentially to $1.71 billion, while organic revenue declined 0.7% year-over-year.”
“We delivered another solid quarter with sequential improvement to all key financial metrics, with reported revenue of $1.7 billion. Organic revenue declined 2%, modestly above the midpoint of our guidance, driven by stable conditions in the lab and improved demand in our production business, especially bioprocessing.”
Start not stated–present
Last confirmed April 13, 2021
Start not stated–2024-03-29
Last confirmed by a filing; no departure on record
AVTR
Medical Instruments & Supplies · Healthcare
CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Avantor, Inc. (AVTR) | Former Chief Executive Officer | $1,140,000 | $13,077,931 |
| 2024 | Avantor, Inc. (AVTR) | Former Chief Executive Officer | $1,126,846 | $14,525,638 |
| 2023 | Avantor, Inc. (AVTR) | Director, President and Chief Executive Officer | $1,140,000 | $12,338,767 |
| 2022 | Avantor, Inc. (AVTR) | Director, President and Chief Executive Officer | $1,127,308 | $10,831,766 |
| 2021 | Avantor, Inc. (AVTR) | Director, President and Chief Executive Officer | $1,085,000 | $13,260,913 |
| 2020 | Avantor, Inc. (AVTR) | Director, President and Chief Executive Officer | $1,085,000 | $11,257,062 |
| 2019 | Avantor, Inc. (AVTR) | Director, President and Chief Executive Officer | $984,308 | $16,995,265 |